21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210)

Rosenberg, J.; Petrylak, Daniel P.; Abidoye, Oyewale O.; Heijden, Michiel S. van der; Hofman-Censits, J.; Necchi, Andrea; O’Donnell, Patrick; Balmanoukian, Ani Sarkis; Loriot, Yohann; Retz, M.; Pérez-Gracia, José Luis; Dawson, Nancy A.; Balar, Arjun Vasant; Galsky, Matt D.; Fleming, Mark T.; Powles, Thomas; Cui, Na; Mariathasan, Sanjeev; Fine, Gregg; Dreicer, R.

doi:10.1016/s0959-8049(16)31942-6

Cited by 19 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, interim results from a key phase II study of atezolizumab (IMvigor 210) in patients with locally advanced or metastatic urothelial carcinoma showed that median overall survival in this heavily pretreated population was 11.4 months in patients with higher levels of PD‐L1 expression, and 7.9 months in the overall study population. Atezolizumab was well tolerated and adverse events were consistent with those observed in previous studies .…”

Section: Impact Of Immune‐based Therapies On Bladder Renal and Prostsupporting

confidence: 85%

Recent advances in immuno‐oncology and its application to urological cancers

Mataraza¹,

Gotwals²

2016

BJU International

View full text Add to dashboard Cite

Recent advances in immuno-oncology have the potential to transform the practice of medical oncology. Antibodies directed against negative regulators of T-cell function (checkpoint inhibitors), engineered cell therapies and innate immune stimulators, such as oncolytic viruses, are effective in a wide range of cancers. Immune'based therapies have had a clinically meaningful impact on the treatment of advanced melanoma, and the lessons regarding use of single agents and combinations in melanoma may be applicable to the treatment of urological cancers. Checkpoint inhibitors, cytokine therapy and therapeutic vaccines are already showing promise in urothelial bladder cancer, renal cell carcinoma and prostate cancer. Critical areas of future immuno-oncology research include the prospective identification of patients who will respond to current immune-based cancer therapies and the identification of new therapeutic agents that promote immune priming in tumours, and increase the rate of durable clinical responses.

show abstract

Section: Impact Of Immune‐based Therapies On Bladder Renal and Prostsupporting

confidence: 85%

Recent advances in immuno‐oncology and its application to urological cancers

Mataraza¹,

Gotwals²

2016

BJU International

View full text Add to dashboard Cite

show abstract

“…Higher expression levels of PD-L1 are associated with increased ORRs to PD-1/PD-L1 blockade, although negative staining for this protein does not preclude durable and/or complete responses in patients with metastatic bladder cancer 143 (TABLE 7). Thus, an urgent need exists for the identification of biomarkers beyond PD-L1 expression that can help predict treatment outcomes.…”

Section: Immune-checkpoint Inhibitorsmentioning

confidence: 99%

Systemic, perioperative management of muscle-invasive bladder cancer and future horizons

Funt

Rosenberg

2016

Nat Rev Clin Oncol

View full text Add to dashboard Cite

Many patients diagnosed with muscle-invasive bladder cancer (MIBC) will develop distant metastatic disease. Over the past three decades, perioperative cisplatin-based chemotherapy has been investigated for its ability to reduce the number of deaths from bladder cancer. Insufficient evidence is available to fully support the use of such chemotherapy in the adjuvant setting; however, neoadjuvant cisplatin-based combination chemotherapy has become a standard of care for eligible patients based on the improved disease-specific and overall survival demonstrated in two randomized phase III trials, compared with surgery alone. For patients with disease downstaging to non-MIBC at the time of radical cystectomy as a result of neoadjuvant chemotherapy, outcomes are outstanding, with 5-year overall survival of 80–90%. Nevertheless, the inability to define before treatment the patients who will and those who will not achieve such a response has impeded the achievement of better outcomes for patients with MIBC. High-throughput DNA and RNA profiling technologies might help to overcome this barrier and enable a more-personalized approach to the use of cytotoxic neoadjuvant chemotherapy. In the past 2 years, trial results have demonstrated the unprecedented ability of immune-checkpoint blockade to induce durable remissions in patients with metastatic disease that has progressed after chemotherapy; studies are now urgently needed to determine how best to incorporate this powerful therapeutic modality into the care of patients with MIBC. Herein, we review the evolution of chemotherapy and immunotherapy for muscle-invasive bladder cancer.

show abstract

“…In patients with elevated levels of tumor PD-L1, impressive response rates (12 CRs, 35 PRs) were recorded. Grade 3-4-toxicities occurred in 15 % of patients [44].…”

Section: Systemic Therapy Of Muscle Invasive or Metastatic Bladder Camentioning

confidence: 99%

Treatment of elderly patients with advanced urological cancer

Niedersuess-Beke

Strasser‐Weippl

2016

memo

View full text Add to dashboard Cite

The treatment of advanced urological cancers has evolved tremendously over the last decade. As the incidence of these cancers is increasing with age, uro-oncologists are increasingly faced with the challenge of choosing optimal therapeutic strategies for elderly patients. Comorbidities interfering with cancer treatment can be identified by geriatric assessment tools that should be applied in elderly cancer patients before starting therapy. Using these tools competing risks of morbidity and mortality can be evaluated. We provide a review on evidence based treatments in elderly prostate, bladder and renal cell carcinoma patients.

show abstract

21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210)

Cited by 19 publications

References 0 publications

Recent advances in immuno‐oncology and its application to urological cancers

Recent advances in immuno‐oncology and its application to urological cancers

Systemic, perioperative management of muscle-invasive bladder cancer and future horizons

Treatment of elderly patients with advanced urological cancer

Contact Info

Product

Resources

About